Nls Pharmaceutics Ag Stock Performance
| NLSPW Stock | USD 0.01 0 11.11% |
NLS Pharmaceutics holds a performance score of 10 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of 4.37, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, NLS Pharmaceutics will likely underperform. Use NLS Pharmaceutics downside variance, as well as the relationship between the daily balance of power and period momentum indicator , to analyze future returns on NLS Pharmaceutics.
Risk-Adjusted Performance
10 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in NLS Pharmaceutics AG are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal basic indicators, NLS Pharmaceutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | NLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance with Nasdaq Continued Listing Rules - Yahoo Finance | 10/15/2024 |
2 | NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements | 10/28/2024 |
3 | NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists in Narcolepsy and Neurological Diso... | 11/18/2024 |
| Begin Period Cash Flow | 8.9 M |
NLS |
NLS Pharmaceutics Relative Risk vs. Return Landscape
If you would invest 1.30 in NLS Pharmaceutics AG on September 1, 2024 and sell it today you would lose (0.30) from holding NLS Pharmaceutics AG or give up 23.08% of portfolio value over 90 days. NLS Pharmaceutics AG is currently producing 4.7145% returns and takes up 36.3254% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than NLS, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
NLS Pharmaceutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for NLS Pharmaceutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as NLS Pharmaceutics AG, and traders can use it to determine the average amount a NLS Pharmaceutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1298
| Best Portfolio | Best Equity | NLSPW | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 36.33 actual daily | 96 96% of assets are less volatile |
Expected Return
| 4.71 actual daily | 94 94% of assets have lower returns |
Risk-Adjusted Return
| 0.13 actual daily | 10 90% of assets perform better |
Based on monthly moving average NLS Pharmaceutics is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of NLS Pharmaceutics by adding it to a well-diversified portfolio.
NLS Pharmaceutics Fundamentals Growth
NLS Stock prices reflect investors' perceptions of the future prospects and financial health of NLS Pharmaceutics, and NLS Pharmaceutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on NLS Stock performance.
| Return On Asset | -2.28 | ||||
| EBITDA | (11.8 M) | ||||
| Net Income | (12.17 M) | ||||
| Cash And Equivalents | 145.4 K | ||||
| Cash Per Share | 0.02 X | ||||
| Total Debt | 1.63 M | ||||
| Current Ratio | 0.05 X | ||||
| Book Value Per Share | (9.40) X | ||||
| Cash Flow From Operations | (9.68 M) | ||||
| Market Capitalization | 37.77 M | ||||
| Total Asset | 1.85 M | ||||
| Retained Earnings | (70.37 M) | ||||
| Working Capital | (6.1 M) | ||||
About NLS Pharmaceutics Performance
Evaluating NLS Pharmaceutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if NLS Pharmaceutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if NLS Pharmaceutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -1.2 K | -1.2 K | |
| Return On Tangible Assets | (6.59) | (6.92) | |
| Return On Capital Employed | 1.94 | 2.04 | |
| Return On Assets | (6.59) | (6.92) | |
| Return On Equity | 1.38 | 1.45 |
Things to note about NLS Pharmaceutics performance evaluation
Checking the ongoing alerts about NLS Pharmaceutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for NLS Pharmaceutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| NLS Pharmaceutics is way too risky over 90 days horizon | |
| NLS Pharmaceutics has some characteristics of a very speculative penny stock | |
| NLS Pharmaceutics appears to be risky and price may revert if volatility continues | |
| NLS Pharmaceutics has high likelihood to experience some financial distress in the next 2 years | |
| NLS Pharmaceutics AG has accumulated 1.63 M in total debt. NLS Pharmaceutics has a current ratio of 0.05, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Note, when we think about NLS Pharmaceutics' use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (12.17 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| NLS Pharmaceutics AG has accumulated about 145.4 K in cash with (9.68 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| NLS Pharmaceutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from accesswire.com: NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists in Narcolepsy and Neurological Disorders |
- Analyzing NLS Pharmaceutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether NLS Pharmaceutics' stock is overvalued or undervalued compared to its peers.
- Examining NLS Pharmaceutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating NLS Pharmaceutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of NLS Pharmaceutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of NLS Pharmaceutics' stock. These opinions can provide insight into NLS Pharmaceutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for NLS Stock Analysis
When running NLS Pharmaceutics' price analysis, check to measure NLS Pharmaceutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NLS Pharmaceutics is operating at the current time. Most of NLS Pharmaceutics' value examination focuses on studying past and present price action to predict the probability of NLS Pharmaceutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NLS Pharmaceutics' price. Additionally, you may evaluate how the addition of NLS Pharmaceutics to your portfolios can decrease your overall portfolio volatility.